Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Clinical application of responder cell frequency estimates with four years of follow up.

Hayward AR, Zerbe GO, Levin MJ.

J Immunol Methods. 1994 Mar 29;170(1):27-36.

PMID:
8157986
2.

In vitro measurement of human T cell responses to varicella zoster virus antigen.

Hayward AR.

Arch Virol Suppl. 2001;(17):143-9. Review.

PMID:
11339543
3.
4.
5.

Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect.

Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR.

J Infect Dis. 1998 Nov;178 Suppl 1:S109-12.

PMID:
9852987
6.
7.

Cytokine production in varicella-zoster virus-stimulated cultures of human blood lymphocytes.

Hayward AR, Cosyns M, Jones M, Levin MJ, Villanueba E, Weinberg A, Chan CY.

J Infect Dis. 1998 Nov;178 Suppl 1:S95-8.

PMID:
9852984
8.

Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.

Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ.

J Infect Dis. 2003 Nov 1;188(9):1336-44. Epub 2003 Oct 17.

PMID:
14593591
9.

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.

Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.

Cancer Immunol Immunother. 2000 Dec;49(10):517-29.

PMID:
11129322
10.

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.

Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM.

Pediatr Infect Dis J. 1995 Oct;14(10):874-9.

PMID:
8584315
12.

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older.

Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR.

Vaccine. 2000 Jun 15;18(25):2915-20.

PMID:
10812235
13.

Subsets of T-cells and in vitro cytokine production after measles and varicellae-zoster virus antigen stimulation in allogeneic BMT patients.

Pauksen K, Sjölin J, Linde A, Andersson B, Lenkei R, Oberg G, Ljungman P.

Scand J Infect Dis. 1999;31(1):43-9.

PMID:
10381217
14.

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.

Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H.

Vaccine. 2000 Feb 25;18(16):1700-6.

PMID:
10689152
15.

Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses.

Jordan GW, Merigan TC.

J Infect Dis. 1974 Nov;130(5):495-501. No abstract available.

PMID:
4370611
16.

Cytokine production in varicella-zoster virus-stimulated lymphocyte cultures.

Zhang Y, White CJ, Levin M, Hayward A.

Neurology. 1995 Dec;45(12 Suppl 8):S38-40.

PMID:
8545017
17.

Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ.

Clin Diagn Lab Immunol. 2001 Sep;8(5):871-9.

18.

Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.

Jacquet A, Haumont M, Massaer M, Garcia L, Mazzu P, Daminet V, Grégoire D, Jacobs P, Bollen A.

Vaccine. 2002 Feb 22;20(11-12):1593-602.

PMID:
11858867
19.

The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine.

Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, Isganitis K, White CJ, Kuter B, Chua J, Starr S.

J Infect Dis. 1993 Dec;168(6):1356-60.

PMID:
8245520
20.

Ten year follow-up of healthy children who received one or two injections of varicella vaccine.

Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I; Study Group for Varivax..

Pediatr Infect Dis J. 2004 Feb;23(2):132-7.

PMID:
14872179

Supplemental Content

Support Center